Policy

Value in Health Care

Background

In 2016, the United States government began to take an interest in using the work of groups like the Institute for Clinical and Economic Review (ICER), which uses available evidence to examine the value of therapeutics and suggest reasonable prices for them, to inform policy decisions. ICER and organizations like it base their work on complex conceptual frameworks that combine an  estimation of the clinical value of a particular drug with several other factors, including the drug’s overall budget impact.

PMC is working to ensure that these organizations account for the challenges involved in assessing the value of personalized medicines when conducting their analyses.

2016

ICER's National Call for Proposed Improvements to Its Value Assessment Framework

ICER's Scoping Document for Non-Small Cell Lung Cancer